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Abstract
Background: Drug discovery and development are predicated on elucidation of the potential mechanisms of action and
cellular targets of candidate chemical compounds. Recent advances in high-content imaging techniques allow simultaneous
analysis of a range of cellular events. In this study, we propose a novel strategy to identify drug targets by combining
genetic screening and high-content imaging in yeast.
Methodology: In this approach, we infer the cellular functions affected by candidate drugs by comparing morphologic
changes induced by the compounds with the phenotypes of yeast mutants.
Conclusions: Using this method and four well-characterized reagents, we successfully identified previously known target
genes of the compounds as well as other genes involved with functionally related cellular pathways. This is the first
demonstration of a genetic high-content assay that can be used to identify drug targets based on morphologic phenotypes
of a reference mutant panel.
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Introduction
Medications exert their pharmacologic effects by interacting with
a wide range of cellular components. To facilitate drug discovery
and development, methods are needed to identify cellular targets
and elucidate the mechanisms of action of candidate chemical
compounds. Conventional drug screening approaches that focus on
specific biochemical activities allow the identification of compounds
that target the particular activities, but the selected compounds
often have multiple in vivo targets that must be identified. Alternative
approaches involve cell-based screens that account for interactions
within the whole cell; however, in vivo targets must still be identified
because cell-based screens focus on the desired cellular response
rather than the biomolecular activity of the targets.
A recent study in Saccharomyces cerevisiae used a comprehensive
panel of yeast deletion mutants and microarray technology to
facilitate the identification of the intracellular targets of a
compound [1]. For example, mutants that show a specific
sensitivity or resistance to a candidate drug can be selected from
the yeast mutant pool using a fitness-based approach combined
with a yeast DNA barcode array [2,3,4]. Alternatively, a
compendium approach examining multiple cellular response
parameters (e.g., gene expression levels and growth rates) can be
used to infer the drug targets of a novel compound based on
reference bioactivity profiles of well-characterized drugs [5,6].
Fluorescence microscopic imaging is advantageous for high-
content assays that assess in vivo drug effects using multiple cellular
response parameters [7]. To examine a number of intracellular
events in Saccharomyces cerevisiae, we recently developed CalMorph,
a high-throughput, high-resolution, image-processing program
that allows us to analyze and quantitate 501 cell morphology
parameters from fluorescent microscopic images of triple-stained
(cell wall, actin, and nuclear DNA) yeast cells [8]. Using
CalMorph, we phenotyped more than 200 cells for each of 4718
nonessential gene deletions [8]. Our results revealed that deletions
of functionally related genes caused similar morphologic pheno-
types, enabling loci to be functionally assigned to a specific cellular
pathway [8]. Further detailed phenotypic analysis revealed that
calcium treatment induced various morphologic changes in
calcium-sensitive cls mutants, and that functionally related cls
mutants could be grouped based on similarities in the calcium-
induced phenotypes [9]. These results suggest that the cellular
pathways affected by a given reagent can be preliminarily
identified based on phenotypic similarities induced by that
reagent. Based on these observations, we hypothesized that genetic
targets can be inferred using multiparameter comparisons of
drug- and mutation-induced morphologic changes.
Here we present a proof-of-concept study that employed four
well-characterized bioactive compounds. We developed a Java-
based program that uses an inference algorithm to estimate
similarities between induced morphologic changes. Using this
algorithm to examine 4718 nonessential gene deletion mutants,
the previous known target genes of the compounds and the
functionally related genes to these targets were successfully
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10177identified and potentially affected cellular pathways were revealed,
demonstrating the validity of this approach.
Results
A high-content image-profiling method
We assumed that dose-dependent morphologic changes induced
by a chemical compound would resemble the effects of mutations in
genes encoding targets of the compound. Therefore, to infer the
targets of potential drugs, we established a high-content, image-
profiling procedure. First, to minimize side effects caused by high
concentrations of the chemicals, the maximum treatment concen-
tration of eachchemicalcompound wasdefined as the concentration
thatproduceda slight delayinthe growthrate of wild-type yeastcells
(approximately 10%of control samples). Three lower concentrations
were then selected and wild-type yeast cells were treated with or
withoutthechemicalcompound at the variousconcentrations.Wild-
type yeast cells grown in the presence of each concentration were
fixed and stained with fluorescein isothiocyanate-conjugated conca-
navalin A (FITC-ConA) to detect the cell wall component
mannoprotein, rhodamine-phalloidin (Rh-ph) to detect the actin
cytoskeleton, and 49,6-diamidino-2-phenylindole (DAPI) to detect
nuclear DNA. Samples from five independent cultures grown in the
presence of each concentration (25 samples for each chemical
compound = fiveconcentrations6fivereplications) were examined
using the image-processing program CalMorph as described
previously [8]. At least 200 cells from each sample were analyzed
for 501 morphologic parameters (see Materials and Methods).
The targets of the chemical compounds were inferred using the
following three steps: I) characterization and principal component
analysis (PCA) of the 4718 deletion mutants; II) characterization
and PCA of wild-type cells treated with the chemical compound;
and III) correlation analysis of the compound-treated and mutant
cells (Figure 1).
To evaluate the 501 parameters in each mutant, the
distributions of each parameter value from the 4718 mutants
were normalized using a Box-Cox power transformation [10].
Parameters for the transformation were estimated from the wild-
type distribution (n=123; Figure 1 I-i and -ii) using a previously
published procedure [8]. Each transformed parameter value for a
mutant represented an abnormality relative to the standard
normal distribution (Figure 1 I-iii and -iv). Next, the 501
morphologic parameters were summarized with PCA because
some of the parameters strongly correlated with each other [8].
We extracted 104 independent axes (principal components) from
the 501 wild-type parameter values (n=123) using PCA at a
cumulative contribution ratio greater than 0.99 (Figure 1 I-v).
Based on the eigenvector calculated from the wild-type data, the
principal component scores for the 104 axes were calculated in
each mutant (Figure 1 I-vi). The scores were then used to represent
an altered morphologic profile that was associated with deletion of
the gene.
To evaluate the dose-dependency of the 501 parameters in
chemically treated wild-type cells, 25 sample values for each
parameter were summarized into a Z score from the Jonckheere-
Terpstra test (Figure 1 II-i and -ii) [11]; this nonparametric
statistical test examines ordered differences among classes (e.g.,
concentrations of the compound). Each Z score represented the
dose-dependency of the parameter under a normal distribution.
Then, the Z scores for the 501 parameters were mapped with the
principal component scores on the 104 axes using the calculated
eigenvector from I-v (Figure 1 II-iii). These scores represented the
altered morphologic profile that resulted from treatment with the
compound.
To evaluate similarities between morphologic changes in drug-
treated wild-type cells and mutant strains, we calculated the
Pearson product-moment correlation coefficient R and the
associated P value for the 104 principal component scores from
the two samples (Figure 1 III). To detect significant similarity, we
estimated two-sided P values by t-test for the correlation
coefficient, and set a level at 0.05 with the Bonferroni correction
dividing a by 4718.
We developed a Java-based program to perform the statistical
estimation, and employed four well-characterized chemical-
compounds (hydroxyurea, concanamycin A, lovastatin, and
echinocandin B) to evaluate our proposed method (Table 1).
Hydroxyurea
Weusedhydroxyureaasarepresentativeofcompoundsthataffect
DNA metabolism. Hydroxyurea is used as an antitumor agent with
antileukemic activity, which results from inhibition of ribonucleotide
reductase activity and consequent suppression of DNA synthesis
[12]. The ribonucleotide reductases are a2b2 tetramers of which
structure is highly conserved from bacteria to mammal [13]. The a
subunit catalyses reduction of ribonucleotide (Rnr1p and Rnr3p in
yeast), whereas the b subunit (Rnr2p and Rnr4p in yeast) producing
radicals required for reductase activity of a subunit [14]. The effect
of hydroxyurea which quenches the enzyme’s tyrosyl radical is
specific for radical-producing b subunit [15,16]. The essential RNR2
gene was not evaluated in this study because the rnr2 mutant was not
included among the tested 4718 mutants.
Wild-type cells were treated with each concentration of
hydroxyurea (Table 1) and photographed (Figure 2A). Images
were analyzed using CalMorph and 501 morphologic parameter
values were obtained. Using the Jonckheere-Terpstra test, 176,
249, 302, and 366 of the 501 parameters were found to show dose-
dependent changes at false discovery rate (FDR) =0.01, 0.05,
0.10, and 0.20, respectively [11,17]. The dose-dependent changes
in the 176 parameters (Table S1) indicated that the hydroxyurea-
treated wild-type yeast cells were enlarged, with delocalized actin
patches in buds and numerous mononuclear budding cells, all of
which are typical phenotypes of cells arrested at the S phase of the
cell cycle.
To identify mutant cells with similar morphologic profiles, we
applied the high-content image profiling on the phenotypic
information of the mutants (Figure 1). Among the 4718 mutants,
384(8.14%)morphologicprofilesweresignificantlysimilarwith that
of the hydroxyurea-treated cells by the high-content image-profiling
at two sided P,0.05 with the Bonferroni correction (Figure 2B).
Among the 100 top-ranked mutants (R.0.629), 12 mutants,
including a rnr4 mutant, were categorized as belonging to a
‘‘DNA replication’’ in the gene ontology (GO) database (GOID:
6260). Enrichment for this GO term was significant by GO term
finder at P,0.05 (Table S2) [18,19], demonstrating that high-
content image profiling efficiently identified genes from pathways
related to the function of Rnr4p. Among the three ribonucleotide
reductasemutantsinthe mutantpanel,thernr1(R =0.592) and rnr4
(R =0.836) mutants were identified based on similar morphologic
phenotypes in these mutants and hydroxyurea-treated wild-type
yeast (Figure 2B and C, Table 2). Interestingly, among 4718
mutants, disruption of rnr4, which encodes the target of hydroxy-
urea, was associated with the highest R value (Figure 2B).
To investigate whether the utility of high-content image
profiling is related to the strength of the mutant phenotypes, we
examined the number of parameters affected by deletion of genes
encoding various targets of hydroxyurea (rnr1, rnr3, and rnr4). Of
the 254 parameters with distributions that could be transformed
into a normal distribution [8], 1, 53, and 62 parameters from the
High-Content Image-Profiling
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10177Figure 1. Schematic of the high-content, image-profiling method used in this study. Yellow histograms in I-i and I-ii indicate the original
and transformed distributions of 123 wild-type values for each parameter, respectively. Gray histograms in I -iii and I-iv indicate the original and
transformed distributions of parameter values for the 4718 mutants, respectively. In I-i, I-ii, I-iii, and I-iv, the vertical and the horizontal histogram axes
represent the frequencies and parameter values, respectively. Box plots in II-i and II-ii indicate the distributions of the parameter values from drug-
treated wild-type yeast. In the box plots in II-i and II-ii, the vertical and the horizontal axes represent the parameter values and drug concentrations,
respectively. Red arrows in II-ii indicate the direction of trends within the parameter data. PC in I-v, I-vi and II-iii indicates the principal components
defined by PCA of transformed wild-type data for 501 parameters. The vertical and the horizontal axes in the two-dimensional plots in III indicate the
principal component scores for the mutants and drug-treated wild-type cells, respectively. The histogram in III shows the distribution of morphologic
similarities between the dose-dependent changes induced drug treatment and those induced by the deletion mutations. Morphologic similarities
were defined using the Pearson product-moment correlation coefficient (R); mutants with significantly high positive R values (the gray region in the
histogram) were defined as potential targets at two sided P ,0.05 with the Bonferroni correction, which was calculated based on P values from the
correlation coefficient test.
doi:10.1371/journal.pone.0010177.g001
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different (P ,0.0001) on one side of the wild-type distribution
(Figure 2A), indicating that the rnr4 and rnr1 mutants had strong
phenotypes relative to the rnr3 phenotype. The weak phenotype of
the rnr3 mutant, which was not identified as a potential
hydroxyurea target, suggested that Rnr3p plays only a minor role
in these cellular processes, and that our high-content image-
profiling method does not detect weak morphologic phenotypes
associated with minor cellular activities.
Concanamycin A
We used concanamycin A as a representative of compounds
that affect intracellular cation homeostasis. Concanamycin A
inhibits the proliferation of mouse splenic lymphocytes stimulated
by concanavalin A [20], and has been shown to be a specific
inhibitor of vacuolar proton-translocating ATPases (V-ATPases)
[21]. V-ATPase, a heteromultimeric enzyme consisting of at least
15 subunits (Vma1p-Vma11p, Vma13p, Vma16p, Vph1p, and
Stv1p), uses ATP hydrolysis to transport cytosolic protons into
vacuoles, resulting in acidification of these compartments [22].
V-ATPase consists of two multimeric subunits; one is hydrophilic
V1 subunit consisting of 8 components, and the other is
hydrophobic VO subunit consisting of 7 components [22]. The
photo activated concanamycin A analog binds to subunit c in VO
domain from Manduca sexta [23], and also in yeast, the binding is
specific to subunit c (among c, c9 and c0 subtypes) encoded by
VMA3 in yeast [24]. Because the vma9 and vma10 mutants were not
included in the mutant panel, we assessed deletions of genes
encoding the other 13 V-ATPase subunits.
Wild-type cells were treated with various concentrations of
concanamycin A (Table 1), and examined using the same method
described above (Figure 3A). Among the 501 parameters, 0, 54,
111, and 217 parameters showed significantly dose-dependent
effects based on the Jonckheere-Terpstra test at FDR =0.01, 0.05,
0.10, and 0.20, respectively [11,17]. Overall, changes in the 54
most sensitive parameters (Table S3) indicated that concanamycin
A treatment resulted in rounder cells with bigger nuclei, and fewer
mononuclear budded cells were present, all of which are indicative
of defective vacuolar acidification.
High-content image profiling revealed that among the 4718
mutants, 221 (4.68%) were significantly similar to concanamycin
A-treated cells at two sided P,0.05 with the Bonferroni correction
(Figure 3B). Among the 100 most likely candidates (R.0.497),
nine mutants including vma3 were associated with ‘‘vacuolar
acidification’’ (GOID: 7035), which represented a significant
enrichment of this GO term (P,0.05, Table S4) [18,19]. Thus,
our method efficiently identified genes encoding proteins in
pathways related to V-ATPase. The 8 of 13 V-ATPase mutants
were identified (Figure 3B). The maximum R value for the 13
V-ATPase mutants was 0.685 for the vma6 mutant (Figure 3C).
These results suggested that the morphologic features of the 8
mutants were similar to the dose-dependent morphologic changes
induced by concanamycin A. Moreover, the 8 V-ATPase mutants
among the 221 candidates represented a significant enrichment
from the original sample of 13 V-ATPase mutants in the complete
panel of 4718 mutants (P=2.45E-7; one-side binomial test).
Because Vma1p, Vma8p, Vma11p, Vph1p and Stv1p do not
directly interact with the drugs [23,24,25], it is not surprising that
they were failed to be identified as the candidates. However, other
V-ATPase mutants were able to be detected even if they do not
directly interect, suggesting that the functional relationships of the
drug target with these components is potentially detected. Then,
we reasoned that the undetected V-ATPase mutants show too
weak phenotypes. To test the effects of the strength of observed
mutant phenotype, we compared the numbers of parameters that
were changed by the various V-ATPase gene deletions. Among the
254 parameters with distributions that could be transformed into a
normal distribution [8], 32, 23, 21, 15, 10, 8, 6, 3, and 2
parameters were identified with a normal distribution (P,0.0001)
on one side from the vma6, vma7, vma5, vma4, vma3, vma2, vma16,
vma1, and vma11 mutants, respectively, whereas no parameters
were detected for the vma8, vma13, vph1, and stv1 mutants.
Therefore, the vma1, vma8, vma11, vph1 and stv1 were not detected
as candidate targets because of the mutants’ weak phenotypes.
Lovastatin
We used lovastatin as a representative of compounds that affect
lipid metabolism. Lovastatin is a cholesterol-lowering agent that
disrupts cholesterol synthesis by specifically inhibiting hydroxy-
methylglutaryl-coenzyme A (HMG-CoA) reductase in the meval-
onate pathway [26]. HMG-CoA reductases encoded by HMG1
and HMG2 in yeast are the rate-limiting enzyme in the sterol
biosynthetic pathway [27].
Wild-type cells were treated with various concentrations of
lovastatin (Table 1) and the cells were characterized using
CalMorph (Figure 4). Jonckheere-Terpstra tests at FDR =0.20
identified significant dose-dependent effects for 56 of the 501
parameters [11,17]. Overall, the changes indicated that lovastatin
treatment made wild-type yeast cells smaller and rounder, and
decreased the percentage of large bud cells (Table S5).
High-content image profiling detected 100 (2.12%) of the 4718
genes as potential lovastatin targets at two sided P,0.05 with the
Bonferroni correction (Figure 4B). Three of the mutated genes,
including fen2, were associated with ‘‘vitamin transporter activity’’
(GOID:51183),a GOtermthat wassignificantlyenriched (P,0.05,
Table S6) among the top 100 candidate targets (R.0.417). Fen2p is
a plasma membrane H
+-pantothenate symporter [28] and CoA is
synthesized from pantothenate [29], demonstrating that our high-
content image-profiling method identified genes from pathways
related to the mevalonate pathway. Although the hmg2 mutant was
not detected as a candidate, the mutant of the lovastatin target hmg1
was identified (R=0.520; Figure 4B and C).
Table 1. Chemical compounds used in this study.
Compound Concentrations Target cellular process Target genes
Hydroxyurea 0, 5.0, 10, 20 and 30 mM Deoxynucleotide triphosphate synthesis RNR1, RNR2, RNR3 and RNR4
Concanamycin A 0, 2.0, 3.9, 7.8 and 15 mM Vacuolar acidification VMA1, VMA2, VMA3, VMA4, VMA5, VMA6, VMA7, VMA8,
VMA9, VMA10, VMA11, VMA13, VMA16, VPH1 and STV1
Lovastatin 0, 6.25, 12.5, 25 and 50 mg/ml Mevalonate synthesis HMG1 and HMG2
Echinocandin B 0, 0.5, 1, 2 and 3 mg/ml 1,3-beta-glucan synthesis FKS1 and FKS2
doi:10.1371/journal.pone.0010177.t001
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the hmg1 and hmg2 mutants with normal distributions on one side
at P,0.0001, suggesting that our high-content image-profiling
method can detect mutants of genes with major cellular roles even
if the mutant show a weak phenotype.
Echinocandin B
We used echinocandin B as representative of agents that
damage the cell wall. Echinocandin B, which is produced by
Aspergillus nidulans and Aspergillus rugulosus [30], has an antifungal
activity owing to an specific inhibition of the synthesis of 1,
Figure 2. Hydroxyurea treatment and the results of target inference. A) Photographs of wild-type cells treated with 30 mM hydroxyurea and
the rnr4 mutant. Cells were triply stained with FITC-ConA, Rh-ph, and DAPI. Quantitative analysis of the hydroxyurea-induced morphologic changes is
summarized in Table S1. B) A histogram of correlation coefficients (R) between the mutant and hydroxyurea-treated wild-type cells. The dashed red
line indicates the position of the R value corresponding to the two sided P value of 0.05 with the Bonferroni correction based on a correlation
coefficient test. C) Two-dimensional plot of wild-type cells treated with hydroxyurea and the rnr4 mutant. The scores for the 104 principal
components are plotted. The red line indicates a linear regression model (R =0.738).
doi:10.1371/journal.pone.0010177.g002
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Because both Fks1p and Fks2p have been identified as the catalytic
subunit of 1,3-b-D-glucan synthase and the synthase activity of a
fks1 mutant was reported to be significantly lower than those of
wild-type cells and a fks2 mutant [32,33], we believe Fks1p is a
representative target of echinocandin B.
Using Jonckheere-Terpstra tests at FDR =0.01, 226 of 501
parameters showed significant dose-dependency in response to
echinocandin B treatment (Table S7 and Table 1). The
echinocandin B-treated wild-type yeast cells were larger and
rounder with bigger nuclei and necks. The cells contained
delocalized actin and fewer large buds were observed.
Among the 4718 mutants, 197 (4.18%), were detected as
candidates using high-content image profiling at two sided P,0.05
with the Bonferroni correction. In the top 100 candidates, three
mutants that were categorized as having ‘‘a-1,6-mannosyltranser-
ase activity’’ (GOID: 9) were identified, which was a significant
enrichment of this GO term (P,0.05, Table S8) [18,19]. The
results demonstrate that our high-content image-profiling method
efficiently identified genes from pathways related to cell wall
biosynthesis, although neither fks1 nor fks2 mutant were included
in the candidates.
Based on previous results [8], 10 of the 254 parameters for the
fks1 mutant showed normal distributions on one side (P,0.0001),
whereas no parameters were detected for the fks2 mutant Since,
it has been suggested that Fks1p has other functions than 1,
3-b-glucan synthesis, a combination of the redundancy and the
multifunctionality might make it difficult to detect the targets, even
if the phenotype is not so weak [34,35].
Discussion
We developed a high-content image-profiling system to identify
drug targets systematically. The multiparameter profiling method
uses 501 morphologic parameters and a dataset of 4718
nonessential deletion mutants (Figure 1). We used four well-
characterized compounds that affect various cellular functions as
test cases (Table 1). The drug target candidates were successfully
screened into 2% to 8% from 4718 mutants on the panel, and the
previously reported targets of the compounds and gene products
associated with pathways that were functionally related to the
target were enriched among the candidates. These results indicate
that our high-content image-profiling method can detect targets of
drug candidate and uncover their potential mechanisms of action.
The proposed method allows systematic, high-content screening
independent of previous information about the drug candidate.
The systematic approach with defined statistical criteria means
that this method can theoretically be used not only to identify
candidates of the drug targets but also to assess the effects of any
condition that induces morphologic changes (e.g., genetic muta-
tions, nutritional starvation, and temperature shifts, among
others). Further, because the analysis is statistics-based, the
methodology can be expanded to higher eukaryotes if a
morphologic phenotype database is available. The statistical
power and utility of the method are enhanced by the multiple
parameters that are extracted from high-resolution images.
Examination of multiple intracellular activities and detailed
phenotypic information for each mutant allow assessments of the
effects of a drug on a wide variety of cellular functions. Our high-
content image-profiling method also allows direct and systematic
identification of drug targets from 4718 nonessential genes without
any prior knowledge of about the mechanism of action of the
candidate drug. This contrasts with conventional high-content
imaging approaches, which focus on specific bioactivities (e.g.,
translocation of fluorescently labeled cellular targets between
intracellular compartments) to assign the drug candidate into well-
characterized groups [36,37]. In addition, the off-target effects
may be estimated by comparing results from low concentration of
the drug treatment (reflecting target-specific effect) with that from
high concentration (reflecting non-specific effects).
Compendium approaches that have been used with microarray
technology to identify genetic targets comprehensively and
systematically [1,38] are similar approach to ours. In the
compendium approaches, multiparametric profiles similar to that
under the query conditions are surveyed from a collection of
profiles under various conditions (drug, deletion mutants and etc).
The profiles based on the relative gene expression abundance
(,300 profiles of ,6000 genes) [5], the synthetic lethality (,1700
profiles of ,3900 genes) [39] and the fitness (,80 profiles of
,3400 genes) [6] are used as compendium data set. These
compendium approaches used hydroxyurea as a test case to assess
feasibility of target inference, and their results were consistent with
that of this study ([5,6,39] and data not shown). These approaches
and our high-content method may be complementary for target
identification because of different screening criteria (i.e., fitness
versus morphology). Moreover, our approach may be particularly
useful to identify targets of drugs that have no apparent effect on
cellular fitness.
A key point for our high-content image-profiling is to detect the
morphological changes. Therefore, if there are no or very little
morphologic changes, it becomes difficult to identify drug targets.
As expected, candidates with minor morphologic changes could
not be detected. For example, when the drug target is the gene
product possessing functionally redundant proteins (e.g., VPH1
and STV1 [40]) and/or is associated with relatively lower
enzymatic activity (e.g., Rnr3p [41], Hmg2p [27], and Fks2p
[32]). In addition, in the case of a multifunctional protein (e.g.,
Fks1p [34,35]), detection of the target was difficult even with
marked morphologic changes [8]. Nevertheless, as Hmg1p, which
showed almost no morphologic change [8] was identified as the
target candidate of lovastatin, even with very weak phenotype it
may be possible to identify the candidate, suggesting that strong
Table 2. Summary of the inference results.
Number of detected
candidates (FDR =0.01)
Representative
target
R value of the representative
target mutant
Rank of the
target mutant
Hydroxyurea 384 (8.14%) rnr4 0.836 (P,2.20E-16) 1
st
Concanamycin A 221 (4.68%) vma6 0.685 (P=1.11E-15) 4
th
Lovastatin 100 (2.12%) hmg1 0.520 (P=1.55E-8) 20
th
Echinocandin B 197 (4.18%) fks1 0.284 (P=3.51E-3) 527
th
doi:10.1371/journal.pone.0010177.t002
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show weak phenotypes (e.g., vma1, vma8 and vma11). In order to
better the statistical power, improvement in the reference data set
of deletion mutants (e.g., preparation of the replicated data sets)
would be required.
The current version of our high-content image-profiling system
is limited to nonessential genes because morphologic phenotypes
of mutants carrying deletions in essential genes are not available.
Some genetic techniques may allow us to overcome this limitation.
For example, heterozygous deletion mutants in diploid yeast may
Figure 3. Concanamycin A treatment and the results of target inference. A) Photographs of wild-type cells treated with 7.8 mM
concanamycin A and the vma6 mutant. Cells were triply stained with FITC-ConA, Rh-ph, and DAPI. Quantitative analysis of concanamycin A-induced
morphologic changes is summarized in Table S2. B) A histogram of correlation coefficients (R) between mutant and concanamycin A-treated wild-
type cells. The dashed red line indicates the position of the R value corresponding to the two sided P value of 0.05 with the Bonferroni correction
based on a correlation coefficient test. C) Two-dimensional plot of concanamycin A-treated wild-type cells and the vma6 mutant. Scores for the 104
principal components are plotted. The red line represents a linear regression model (R=0.685).
doi:10.1371/journal.pone.0010177.g003
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be screened [2]. Alternatively, a comprehensive set of tempera-
ture-sensitive mutants for essential genes [42], including multiple
mutant alleles of the same gene, may provide intragenic insights
into the inhibitory mechanisms of compounds even if the target
genes are multifunctional (e.g., FKS1 [34,35]). Finally, morpho-
logic information from overexpression mutants may facilitate the
identification of functionally promoted genetic targets [43,44].
To further improve our method, we can examine more image
parameters from of other organelles. The new version of
Figure 4. Lovastatin treatment and the results of target inference. A) Photographs of wild-type cells treated with 50 mg/ml lovastatin and the
hmg1 mutant. Cells were triply stained with FITC-ConA, Rh-ph, and DAPI. Quantitative analysis of lovastatin-induced morphologic changes is
summarized in Table S3. B) A histogram of correlation coefficients (R) between the mutant and lovastatin-treated wild-type cells. The dashed red line
indicates the position of the R value corresponding to the two sided P value of 0.05 with the Bonferroni correction based on a correlation coefficient
test. C) Two-dimensional plot of lovastatin-treated wild-type cells and the hmg1 mutant. Scores for the 104 principal components are plotted. The red
line represents a linear regression model (R=0.512).
doi:10.1371/journal.pone.0010177.g004
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including additional characteristics of various cellular components
such as mitochondria, vacuoles and spindle pole bodies [45]. The
new version of CalMorph should improve the inference accuracy
and generality of this approach for a variety of chemicals by
expanding the available morphologic data from the mutant panel.
Materials and Methods
Media and strain
S. cerevisiae were grown in rich medium consisting of YPD
medium, 1% (w/v) Bacto yeast extract (BD Biosciences, CA,
USA), 2% (w/v) Bacto peptone (BD Biosciences), and 2% (w/v)
glucose. The wild-type S. cerevisiae strain (access number: Y02458:
MATa his3::KanMX leu2 met15 ura3) used in this study was
purchased from the European Saccharomyces cerevisiae Archive for
Functional Analysis (EUROSCARF: http://web.uni-frank
furt.de/fb15/mikro/euroscarf/).
Chemicals and test conditions.
Stock solutions of 2 M hydroxyurea (Sigma-Aldrich, MO, USA),
100 mM concanamycin A (Sigma-Aldrich), 20 mg/ml lovastatin
(Wako Pure Chemical Industries, Osaka, Japan), and 2 mg/ml
echinocandin B (gift from Dr. T. Watanabe) were prepared in
various solvents: distilled water (DW); dimethyl sulfoxide (DMSO)
(Wako Pure Chemical Industries, Ltd.);ethanolicNaOHcontaining
15% (v/v) ethanol (Wako Pure Chemical Industries) and 0.25%
(w/v)NaOH(WakoPureChemicalIndustries)inDW;and DMSO,
respectively.
To grow wild-type yeast treated with each reagent, cells were
precultured in rich medium, and were used to inoculate wells of a
microtiter plate containing fresh rich medium and various
inhibitory concentrations of the reagent or the solvent alone (flat-
bottomed 96-well plates with lids; Asahi Techno Glass Corporation,
Chiba, Japan). The cultures were incubated at 25uC in a shaking
incubator (Micro mixer E-36, Taitec Corporation, Saitama, Japan)
and their optical densities were measured at 600 nm at more than
10 time points over the course of 2 days using a SpectraMax Plus
384
spectrophotometer (Molecular Devices, CA, USA). Growth tests
were performed twice for each reagent, the averaged doubling time
was calculated, and the concentration that delayed the doubling
time by approximately 10% was determined.
Image acquisition and analysis
Cells (8610
6 cells/ml) growing at 25uC in rich medium with or
without various concentrations of each reagent (Table 1) were
fixed in medium supplemented with 3.7% formaldehyde (Wako
Pure Chemical Industries) and 0.1 M potassium phosphate buffer
(pH 6.5). Triple staining of the yeast cells and image analysis with
CalMorph (ver. 1.1) were performed as described previously [8].
CalMorph automatically characterizes each yeast cell by calculat-
ing 501 morphologic parameters based on data from more than
200 cells. Five independent cultures grown under each condition
were analyzed.
Statistical analysis
Calculation of the doubling time and plotting of the analyzed
data was performed using R (http://www.r-project.org/). High-
content image-profiling, including the PCA, Jonckheere-Terpstra
test, Pearson product-moment correlation analysis, and bootstrap-
based estimation of the FDR [17], was performed using a newly
built Java program. The Java program includes a graphical user
interface and is available upon request. Morphologic data about the
4718 mutants and 126 replications of wild-type cells were described
previously [8]. Among the replicated wild-type data, three
replications were discarded because of missing values. A Box-Cox
power transformation was used as described previously [8].
GO::TermFinder, a set of Perl modules, was downloaded from
http://search.cpan.org/dist/GO-TermFinder/and used to exam-
ine enrichment of GO terms in 4718 genes [19]. In order to
implement GO::TermFinder at local computer, two files including
gene information and ontology information were downloaded from
the Sacchromyces Genome Database (http://www.yeastgenome.org/)
[18] and the Gene Ontology website (http://www.geneontology.
org/) [46], respectively.
Supporting Information
Table S1 A list of parameters identified from hydroxyurea-
treated cells using Jonckheere-Terpstra tests at FDR =0.01.
Green, red, and blue in the ‘ID’ column indicate parameters that
were calculated from images of the cell wall, actin, and DNA,
respectively. Red and green in the ‘P value’ column indicate
increases and decreases, respectively, in the parameter values
following hydroxyurea treatment with a given FDR from the
Jonckheere-Terpstra test. All 501 parameters were described
previously. A) A list of parameters detected at stage A (unbudded
cells with one nucleus). B) A list of parameters detected at stage
A1B (budded cells with one nucleus). C) A list of parameters
detected at stage C (budded cells with two nuclei). D) A list of
parameters representing various cellular ratios.
Found at: doi:10.1371/journal.pone.0010177.s001 (0.06 MB
XLS)
Table S2 A list of GO terms enriched in the top 100 genes
ranked by the high-content image-based profiling for hydroxyurea
treatment. Of the 4718 genes, 4379 genes were associated to at
least one GO term, in which 91 of top 100 genes ranked by high-
content image-profiling for hydroxyurea were included. Using the
GO term finder (see Materials and Methods), significant
enrichment of 111 GO terms was detected at P,0.05 with the
Bonferroni correction (Corrected P-value column) among the 91
genes from 4379 genes, and GO terms associated with 100 and
fewer genes in the 4379 genes (Number of annotations in the 4718
genes column) were listed.
Found at: doi:10.1371/journal.pone.0010177.s002 (0.03 MB
XLS)
Table S3 A list of parameters identified from concanamycin A-
treated cells using Jonckheere-Terpstra tests at FDR =0.05. The
color scheme is the same as that used in Table S1. A) A list of
parameters detected at stage A (unbudded cells with one nucleus).
B) A list of parameters detected at stage A1B (budded cells with
one nucleus). C) A list of parameters detected at stage C (budded
cells with two nuclei). D) A list of parameters that represent various
cell ratios.
Found at: doi:10.1371/journal.pone.0010177.s003 (0.04 MB
XLS)
Table S4 A list of GO terms enriched in the top 100 genes
ranked by the high-content image-based profiling for concanamy-
cin A treatment. Of the 4718 genes, 4379 genes were associated to
at least one GO term, in which 90 of top 100 genes ranked by
high-content image-profiling for concanamycin A were included.
Using the GO term finder (see Materials and Methods), significant
enrichment of 89 GO terms was detected at P,0.05 with the
Bonferroni correction (Corrected P-value column) among the 90
genes from 4379 genes, and GO terms associated with 100 and
fewer genes in the 4379 genes (Number of annotations in the 4718
genes column) were listed.
High-Content Image-Profiling
PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e10177Found at: doi:10.1371/journal.pone.0010177.s004 (0.03 MB
XLS)
Table S5 A list of parameters identified from lovastatin-treated
cells using Jonckheere-Terpstra tests at FDR =0.20. The color
scheme is the same as Table S1. A) A list of parameters detected at
stage A (unbudded cells with one nucleus). B) A list of parameters
detected at stage A1B (budded cells with one nucleus). C) A list of
parameters detected at stage C (budded cells with two nuclei). D) A
list of parameters that represent various cell ratios.
Found at: doi:10.1371/journal.pone.0010177.s005 (0.04 MB
XLS)
Table S6 A list of GO terms enriched in the top 100 genes
ranked by the high-content image-based profiling for lovastatin
treatment. Of the 4718 genes, 4379 genes were associated to at
least one GO term, in which 92 of top 100 genes ranked by high-
content image-profiling for lovastatin were included. Using the
GO term finder (see Materials and Methods), significant
enrichment of three GO terms was detected at P,0.05 with the
Bonferroni correction (Corrected P-value column) among the 92
genes from 4379 genes, and GO terms associated with 100 and
fewer genes in the 4379 genes (Number of annotations in the 4718
genes column) were listed.
Found at: doi:10.1371/journal.pone.0010177.s006 (0.02 MB
XLS)
Table S7 A list of parameters identified from echinocandin
B-treated cells using Jonckheere-Terpstra tests at FDR =0.01.
The color scheme is the same as Table S1. A) A list of parameters
detected at stage A (unbudded cells with one nucleus). B) A list of
parameters detected at stage A1B (budded cells with one nucleus).
C) A list of parameters detected at stage C (budded cells with two
nuclei). D) A list of parameters that represent various cell ratios.
Found at: doi:10.1371/journal.pone.0010177.s007 (0.06 MB
XLS)
Table S8 A list of GO terms enriched in the top 100 genes
ranked by the high-content image-based profiling for echinocan-
din B treatment. Of the 4718 genes, 4379 genes were associated to
at least one GO term, in which 84 of top 100 genes ranked by
high-content image-profiling for echinocandin B were included.
Using the GO term finder (see Materials and Methods), significant
enrichment of 52 GO terms was detected at P,0.05 with the
Bonferroni correction (Corrected P-value column) among the 84
genes from 4379 genes, and GO terms associated with 100 and
fewer genes in the 4379 genes (Number of annotations in the 4718
genes column) were listed.
Found at: doi:10.1371/journal.pone.0010177.s008 (0.03 MB
XLS)
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